For example, cyclo(aspartyl-leucyl-threonyl-valyl-tyrosyl-phenylalanylglycyl) (Figure 5c1), a cyclic peptide that can (1) inhibit lipopolysaccharide-induced inflammation and apoptosis by modulating the phosphatidylinositol 3-kinase/protein kinase B (PI3K/Akt) signaling pathway and (2) exhibit anticancer activity against esophageal, pancreatic, lung, and colon cancers (You et al., 2021; Tantai et al., 2016). Here, AKT1 is linked to malignant colon neoplasm.